Our company name, Nirmidas, is based on the Greek myth of the Midas touch, where everything King Midas touched was transmuted into gold; the ‘Nir” portion of the name derives from the centerpiece of our platforms based on our breakthrough near-infrared (NIR) technologies spanning NIR-I (800-1000 nm) and NIR-II/SWIR (1000-1700 nm, short-wave infrared) windows.

Nirmidas has launched both diagnostics and imaging products based on near-infrared fluorescence technologies.

Nirmidas is commercializing diagnostics products for early disease diagnosis, prognosis monitoring and population screening for both point-of-care (POC) deployment and over-the-counter (OTC) home use. Nirmidas seeks FDA clearance for the clinical test kits. Its patented plasmonic gold (pGOLD™) assay platform provides enhanced sensitivity for up to 100 times for biological detections on gold coated microarrays.

Nirmidas’ NIR-II/SWIR probes and in vivo imaging system offer a unique combination to enable researchers performing non-invasive sub-centimeter deep imaging at whole-mouse-body scale and single-cell and single vasculature scale in real time, representing a revolution in fluorescence imaging of small animals. Nirmidas’ novel NIR-II/SWIR probes are further enhanced by patented and proprietary methods of conjugation to antibodies, peptides, and other targeting ligands, allowing in vivo molecular imaging at the whole-body scale and in mouse brain, tumor, and lymph nodes at cellular levels.

Nirmidas registered products with FDA, obtained FDA Emergency Use Authorization, registered products with CE IVD, and is ISO13485:2016 certified, as of 2021.

Nirmidas has contract manufacturing in the U.S., France, and China.

Nirmidas Biotech, Inc. Downloads

MidaSpot - COVID-19 Antibody Combo Detection Kit - Brochure

MidaScan and MidaScan - Model IR - Dual-Channel Confocal Scanner - Brochure

Contact supplier